Chai Discovery

Building frontier AI to engineer better molecules

San Francisco, United States · Founded 2024 · $200.0M raised

Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$200.0M
Last Round
$130.0M Venture RoundDec 2025
Rounds
2

About

Chai Discovery is an AI drug discovery company that develops foundation models for molecular biology, enabling the prediction and design of biochemical interactions with atomic precision. The company's flagship model, Chai-1 and Chai-2, are multi-modal foundation models for predicting molecular structures and de novo antibody design. Chai-2 achieves an 85% success rate in zero-shot antibody discovery. Founded in 2024 by former OpenAI researchers, Chai has partnered with Eli Lilly for AI-driven biologics discovery and raised $130M in a Series B led by General Catalyst. The company operates as a partner-facing R&D and software organization supporting biologics discovery for biopharma customers.

Summary

Chai Discovery is an Artificial Intelligence company based in San Francisco, United States, founded in 2024. It has raised $200.0M in total across 2 rounds, most recently a $130.0M Venture Round round in Dec 2025. Investors include Menlo Ventures.

Tech & App Stack

10 technologies & apps tracked

Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.

Sign up to view the funding chart

Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.

Funding History

Venture RoundFunding RoundDec 2025
$130.0M

Sign up to see all 2 rounds

Full funding history, per-round amounts, and investor participation.

Investors

Similar Companies